Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy

Treatment recommendations for people living with chronic hepatitis B virus (HBV) infection are becoming less stringent, meaning that more of the population will be eligible to receive therapy with nucleos(t)ide analogue agents. We explored outcomes of HBV treatment in a large UK dataset, describing different responses to treatment, and showing that the viral load is not completely suppressed after 1 year in about one in five cases, associated with an increased risk of liver complications. As treatment is rolled out more widely, patients and clinicians need to be aware of the potential for incomplete virologic responses. The findings can support the identification of high-risk individuals, improve early fibrosis and cirrhosis prediction, guide monitoring and preventive interventions, and support public health elimination goals.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2024-10-09
DOI
https://doi.org/10.1016/j.jhepr.2024.101229
Citations
7
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy

Alexander J. Stockdale, Erik Mayer, Stephen Ryder, Juliette Verheyden et al.
7 citations
JHEP Reports
Hepatitis B Virus Studies
2.71
article

Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy

Alexander J. Stockdale, Erik Mayer, Stephen Ryder, Juliette Verheyden, Gail Roadknight, Kinga A. Várnai, William Gelson, Ben Glampson, Finola Higgins, Luca Mercuri, Stephanie Little, J Jaworski, Salim I. Khakoo, Suzanne Maynard, Sarah Montague, Irene Juurlink, William E. Bernal, Michael George, Louise English, Hizni Salih, Lara N. Roberts, Timothy K. Roberts, Yun Kim, Karl McIntyre, Theresa Noble, Ruth Norris, Ashley Heinson, Andrew Frankland, Kathryn Jack, Philippa Clare Matthews, Luis Romão, Lauren Poole, Christopher R. Jones, Ahmed Mohamed Elsharkawy, Florina Borca, Shazaad Ahmad, George Tilston, David Ramlakhan, Tingyan Wang, Cori Campbell, Stacy Todd, Nicholas Easom, Cai Davis, J. O. Meneses, Victoria Day, Javier Vilar, Simon Stanworth, Douglas MacDonald, Heather Rogers, Dimitri Papadimitriou, Heidi MacNaughton, Ilina Serafimova, Alex Waldren-Glenn, Berit Reglar
article en
7 citations

Abstract

Treatment recommendations for people living with chronic hepatitis B virus (HBV) infection are becoming less stringent, meaning that more of the population will be eligible to receive therapy with nucleos(t)ide analogue agents. We explored outcomes of HBV treatment in a large UK dataset, describing different responses to treatment, and showing that the viral load is not completely suppressed after 1 year in about one in five cases, associated with an increased risk of liver complications. As treatment is rolled out more widely, patients and clinicians need to be aware of the potential for incomplete virologic responses. The findings can support the identification of high-risk individuals, improve early fibrosis and cirrhosis prediction, guide monitoring and preventive interventions, and support public health elimination goals.

JHEP ReportsVol. 7(1)
University College Hospital (GB), University of Liverpool (GB), Imperial College Healthcare NHS Trust (GB), The Francis Crick Institute (GB), Cambridge University Hospitals NHS Foundation Trust (GB), Royal Liverpool University Hospital (GB), University Hospital Southampton NHS Foundation Trust (GB), University of Oxford (GB), NIHR Imperial Biomedical Research Centre (GB), UCL Biomedical Research Centre (GB), Oxford BioMedica (United Kingdom) (GB), University of Southampton (GB), University College London (GB), Imperial College London (GB)
GlaxoSmithKline, Roche, Wellcome Trust, Francis Crick Institute, National Institute for Health and Care Research, University of Liverpool, National Institute for Health Research Southampton Biomedical Research Centre, UCLH Biomedical Research Centre, University College London Hospitals Biomedical Research Centre, NIHR Imperial Biomedical Research Centre, NIHR Oxford Biomedical Research Centre, NIHR Cambridge Biomedical Research Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre
Life below water
Openalex Percentile: Top 9%
Hepatitis B Virus Studies
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.